BeGrow Study to Treat Pulmonary Artery (PA) Stenosis in Newborns and Infants

Overview

Objective of the study is to assess safety and performance of the BeGrow Stent System for newborns and infants in pulmonary artery stenosis.

Full Title of Study: “Prospective, Multicenter, Single-arm Study to Assess the Safety and Performance of the BeGrow Stent System in Newborns and Infants to Treat Pulmonary Artery Stenosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 31, 2021

Detailed Description

The Bentley InnoMed "BeGrow Stent System for Newborns and Infants" is a stent delivery system indicated for intraluminal placement in the pulmonary arteries of newborns and infants for the treatment of Pulmonary Artery Stenosis.

Interventions

  • Device: BeGrow Stent System
    • All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System

Arms, Groups and Cohorts

  • Experimental: BeGrow Stent System
    • All enrolled subjects will receive the BeGrow Stent System

Clinical Trial Outcome Measures

Primary Measures

  • Vessel enlargement in mm
    • Time Frame: after procedure and during follow ups up to 12 Months
    • Vessel enlargement will be measured in mm, directly before and after stent implantation by angiography
  • Incidence of serious adverse events device and procedure related
    • Time Frame: 12 Months
    • Incidence of SAE

Participating in This Clinical Trial

Inclusion Criteria

  • Single lesion(s) which can be treated with a 6 mm BeGrow stent (only one stent per lesion allowed). – Pulmonary artery stenosis – patient must at least have one of the following diseases: – Haemodynamically relevant proximal or distal branch pulmonary artery stenosis with a reduction of the vessel diameter when the vessel/patient is large enough to accommodate a stent, – Haemodynamically relevant stenosis of the main pulmonary artery segment that results in elevation of the Right Ventricle (RV) pressure, provided that the stent definitely will not compromise a functioning pulmonary valve and will not impinge on the pulmonary artery bifurcation, – Any degree of stenosis in patients with single ventricle circulation – Critically ill postoperative cardiac patients when it has been determined that branch pulmonary artery stenosis is resulting in a definite haemodynamic compromise in a patient/vessel of any size, particularly if balloon dilatation is unsuccessful – Signed written informed consent (by parents/legal guardians) – Lesion can be accessed with a guide wire or balloon catheter – Age ≤ 24 months and weight ≥ 2 kg – Adequate stent length available Exclusion Criteria:

  • The following lesions are excluded from treatment with BeGrow stent: – Shunt stenosis – Valvular and subvalvular pulmonary stenosis – Patients with known hypersensitivity to the stent material (L605 cobalt-chromium). – Patients with clinical or biological signs of infection. – Patients with active endocarditis. – Patients with known allergy to acetylsalicylic acid, other antiplatelet agents or heparin. – Presence of other previously implanted stents in the same lesion or in close proximity to stent (direct stent-stent contact). – Patients with known coagulation disorder. – Patients where direct stent-stent contact or overlapping cannot be avoided. – Patients where contact to the vessel wall over the entire stent length cannot be ensured after dilatation (especially in short and thick lesions). – Patients where the BeGrow stent could protrude freely into adjacent vessels after expansion/dilatation, including the pulmonary arterial bifurcation. – Implantation of the BeGrow stent in the pulmonary arterial bifurcation.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 24 Months

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bentley InnoMed GmbH
  • Collaborator
    • LS medcap GmbH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Oliver Kretschmar, Prof.Dr.med, Principal Investigator, Kinderspital Zürich, Pädiatrische Kardiologie

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.